Abciximab Pharmacodynamics Are Unaffected by Antecedent Therapy with Other GPIIb/IIIa Antagonists in Non-human Primates

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2003 Mar 26

PMID 12652146

Authors

Marian T Nakada

Patricia M Sassoli

Susan H Tam

Mark A Nedelman

Robert E Jordan

Dean J Kereiakes

Affiliations

Soon will be listed here.

Abstract

Background: Tirofiban and eptifibatide are currently approved for the medical stabilization of non-ST segment elevation acute coronary syndromes. In patients undergoing percutaneous coronary intervention (PCI) during infusion of these drugs, conversion to abciximab, which has long term proven clinical efficacy and cost-effectiveness, following PCI may be desirable. The purpose of this study was to determine if the binding or pharmacodynamics of abciximab is affected by a prior infusion of either tirofiban or eptifibatide.

Methods: In vitro binding experiments were performed to determine if prior exposure to tirofiban or eptifibatide altered the affinity and extent of binding of abciximab to GPIIb/IIIa. For in vivo experiments, cynomolgus monkeys were pretreated with a bolus and 18 hour infusion of saline, tirofiban, or eptifibatide. At the end of the initial treatment, a bolus and 12 hr infusion of abciximab was started without delay. Inhibition of platelet aggregation, GPIIb/IIIa receptor blockade and abciximab pharmacokinetics were measured during and after both infusions.

Results: Equilibrium binding of abciximab in vitro was unaffected by tirofiban or eptifibatide. The extent and duration of abciximab inhibition of ex vivo platelet aggregation, receptor blockade, and abciximab pharmacokinetics in monkeys during and after the abciximab infusion were not affected by prior infusion of the animals with tirofiban or eptifibatide.

Conclusions: In vitro and in vivo studies revealed that the molecular interaction of abciximab with the platelet GPIIb/IIIa receptor is not altered by immediate prior exposure of platelets to small molecule GPIIb/IIIa antagonists. These preclinical studies suggest that the efficacy of abciximab should not be impaired if it is initiated following termination of therapy with small molecule GPIIb/IIIa antagonists.

References

Kleiman N, Raizner A, Jordan R, Wang A, Norton D, Mace K . Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol. 1995; 26(7):1665-71. DOI: 10.1016/0735-1097(95)00391-6. View

Rebello S, Huang J, Faul J, Lucchesi B . Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists. J Thromb Thrombolysis. 1999; 9(1):23-8. DOI: 10.1023/a:1018679708251. View

Smith J, Steinhubl S, Lincoff A, Coleman J, Lee T, HILLMAN R . Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999; 99(5):620-5. DOI: 10.1161/01.cir.99.5.620. View

Marciniak Jr S, Jordan R, Mascelli M . Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thromb Haemost. 2001; 85(3):539-43. View

Lev E, Osende J, Richard M, Robbins J, Delfin J, Rodriguez O . Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function. J Am Coll Cardiol. 2001; 37(3):847-55. DOI: 10.1016/s0735-1097(00)01181-5. View

Upchurch G, Valeri C, Khuri S, Rohrer M, Welch G, MacGregor H . Effect of heparin on fibrinolytic activity and platelet function in vivo. Am J Physiol. 1996; 271(2 Pt 2):H528-34. DOI: 10.1152/ajpheart.1996.271.2.H528. View

Beer J, Springer K, Coller B . Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor. Blood. 1992; 79(1):117-28. View

Barrett J, Murphy G, Peerlinck K, De Lepeleire I, Gould R, Panebianco D . Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther. 1994; 56(4):377-88. DOI: 10.1038/clpt.1994.152. View

Kleiman N, Lincoff A, Flaker G, Pieper K, Wilcox R, Berdan L . Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation. 2000; 101(7):751-7. DOI: 10.1161/01.cir.101.7.751. View

10.

Scarborough R . Development of eptifibatide. Am Heart J. 1999; 138(6 Pt 1):1093-104. DOI: 10.1016/s0002-8703(99)70075-x. View

11.

Boersma E, Akkerhuis K, Theroux P, Califf R, Topol E, Simoons M . Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999; 100(20):2045-8. DOI: 10.1161/01.cir.100.20.2045. View

12.

Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D . Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Circulation. 1999; 99(17):2231-8. DOI: 10.1161/01.cir.99.17.2231. View

13.

Phillips D, Teng W, Arfsten A, White M, Longhurst C, Shattil S . Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997; 96(5):1488-94. DOI: 10.1161/01.cir.96.5.1488. View

14.

. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998; 338(21):1488-97. DOI: 10.1056/NEJM199805213382102. View

15.

Kereiakes D, Runyon J, Kleiman N, Higby N, Anderson L, Hantsbarger G . Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Circulation. 1996; 94(5):906-10. DOI: 10.1161/01.cir.94.5.906. View